Skip to main content
. 2024 Nov 15;16(22):3836. doi: 10.3390/cancers16223836

Figure 3.

Figure 3

ATUX-3364 and ATUX-8385 decreased NB viability. Cells from established NB cell lines SK-N-AS, SK-N-BE(2), SH-EP, and WAC2 were treated with increasing doses of (A) ATUX-3364 (0–20 µM) or (B) ATUX-8385 (0–20 µM) for 24 h. Both compounds significantly decreased viability in all cell lines. (C) COA6 human NB PDX cells were treated with increasing doses of ATUX-3364 or ATUX-8385 (0–25 µM) for 24 h. Both compounds decreased viability. Immunoblotting was performed on whole cell lysates from (D) SK-N-AS and (E) SK-N-BE(2) NB cells following treatment with ATUX-3364 or ATUX-8385. Cleaved PARP (85 kDa) was increased, and total PARP (120 kDa) decreased in SK-N-AS and SK-N-BE(2) whole cell lysates. Data are reported as mean fold change ± SEM, and experiments were repeated with at least three biological replicates. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. The uncropped bolts are shown in Supplementary Materials.